Entering text into the input field will update the search result below

TRYPF Tryp Therapeutics Inc.
Stock Price & Overview

$0.030.003 (+11.11%)1:16 PM 12/08/23
OTCQB | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Tryp Therapeutics Inc. logo
Tryp Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing psilocybin-related molecules. The company’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program focuses on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. Its program candidate includes TRP-8803, a psilocybin-based drug product for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
  • 301 - 1665 Ellis Street
  • Kelowna, BC, V1Y 2B3
  • Canada
Phone Number
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.